Gelesis Holdings, Inc.: Business Overview, Financials & Competitive Analysis

Gelesis Holdings, Inc. Overview

Gelesis Holdings, Inc. was a Boston-based biotherapeutics company specializing in superabsorbent hydrogel therapies for weight management and gastrointestinal-related chronic diseases. The company's flagship product, Plenity (Gelesis100), received FDA clearance (April 2019) as a non-systemic, non-stimulant aid for weight management. However, Gelesis filed for Chapter 7 liquidation in October 2023.

Strategic Profile

Gelesis pioneered a biomimetic approach using naturally-derived hydrogels that mechanically expanded in the stomach to create satiety without systemic effects. The company pursued a diverse pipeline including Gelesis200 for Type 2 Diabetes and investigational candidates for NASH and functional constipation. Despite FDA approval and clinical validation, commercialization challenges and market headwinds led to financial distress.

Competitive Landscape

Gelesis competed in the obesity treatment space against pharmaceutical and medical device competitors including Vivus (oral GLP-1 agonists), NGM Biopharmaceuticals (metabolic disease focus), and oral weight-loss medications from major pharma. The rise of GLP-1 receptor agonists (semaglutide, tirzepatide) by Novo Nordisk and Eli Lilly created significant headwinds for mechanical/non-systemic approaches. Gelesis's mechanical-only mechanism and limited reimbursement differentiated but ultimately constrained its market opportunity.

Industry Context

Gelesis Holdings, Inc. operates in GLP-1 & Obesity Drugs.

Key facts

Founded: 2006 · Headquarters: Boston, MA, USA · Employees: 93 (as of 2023) · Revenue: $12.1M (trailing twelve months as of June 2023) · Market cap: $3.62M (as of August 2023)